Max Backman
ST-läkare vid Institutionen för immunologi, genetik och patologi; Kliniska verksamheter; Klinisk patologi
- E-post:
- max.backman@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
75185 Uppsala - Postadress:
- Rudbecklaboratoriet
75185 Uppsala
Affilierad Forskare vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Patrick Micke
- E-post:
- max.backman@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postadress:
- Rudbecklaboratoriet
751 85 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Akademiska meriter: MD, PhD.
Publikationer
Senaste publikationer
- Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies (2024)
- Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer (2023)
- Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer (2023)
- An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers (2023)
- Fibroblast subsets in non-small cell lung cancer (2023)
Alla publikationer
Artiklar
- Tumor Heterogeneity Confounds Lymphocyte Metrics in Diagnostic Lung Cancer Biopsies (2024)
- Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer (2023)
- Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer (2023)
- An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers (2023)
- Fibroblast subsets in non-small cell lung cancer (2023)
- Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer (2021)
- FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response (2021)
- Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer (2021)
- PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung (2021)
- The Immune Landscape of Colorectal Cancer (2021)
- The prognostic impact of the tumour stroma fraction (2021)
- Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation (2021)
- Proximity Ligation Assay as a Tool for Antibody Validation in Human Tissues (2020)
- ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma (2020)
- Programmed Cell Death Ligand 1 Immunohistochemistry (2019)
- Digital multiplex immunofluorescence analysis identifies immune profiles in the tumor stroma associated with clinical outcome (2018)
- Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients (2018)
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer (2017)
- PD-L1 immunohistochemistry in clinical diagnostics (2017)
- Spatial immunophenotyping of the tumor microenvironment in non-small cell lung cancer
- Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer.
Böcker
